Daprodustat: A potential game-changer in renal anemia therapy-A perspective

The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials.

Automated summary

The FDA has approved daprodustat as the first oral treatment option for anemia in CKD dialysis patients. Clinical trials have shown its efficacy and safety, non-inferior to darbepoetin and potentially reducing IV iron usage. Daprodustat also holds potential for treating anemia in non-dialysis patients with CKD and for patients with both renal anemia and heart failure, pending further research.